RecruitingPhase 3NCT06647953
Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma
Studying DICER1 tumor-predisposition syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Children's Oncology Group
- Principal Investigator
- Kris Ann P SchultzChildren's Oncology Group
- Intervention
- Biospecimen Collection(procedure)
- Enrollment
- 110 enrolled
- Eligibility
- 21 years · All sexes
- Timeline
- 2025 – 2029
Study locations (30)
- Children's Hospital of Alabama, Birmingham, Alabama, United States
- Phoenix Childrens Hospital, Phoenix, Arizona, United States
- Arkansas Children's Hospital, Little Rock, Arkansas, United States
- Loma Linda University Medical Center, Loma Linda, California, United States
- Children's Hospital Los Angeles, Los Angeles, California, United States
- Valley Children's Hospital, Madera, California, United States
- Kaiser Permanente-Oakland, Oakland, California, United States
- Children's Hospital Colorado, Aurora, Colorado, United States
- Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center, Denver, Colorado, United States
- Alfred I duPont Hospital for Children, Wilmington, Delaware, United States
- Children's National Medical Center, Washington D.C., District of Columbia, United States
- Golisano Children's Hospital of Southwest Florida, Fort Myers, Florida, United States
- Nemours Children's Clinic-Jacksonville, Jacksonville, Florida, United States
- Nicklaus Children's Hospital, Miami, Florida, United States
- Arnold Palmer Hospital for Children, Orlando, Florida, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06647953 on ClinicalTrials.govOther trials for DICER1 tumor-predisposition syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT01247597DICER1-related Pleuropulmonary Blastoma Cancer Predisposition Syndrome: A Natural History StudyNational Cancer Institute (NCI)
- ACTIVE NOT RECRUITINGNANCT01464606International Pleuropulmonary Blastoma (PPB) Treatment and Biology RegistryChildren's Hospitals and Clinics of Minnesota